Related Experiment Video
Updated: Jan 17, 2026
06:33
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
Published on: November 10, 2023
1.8K
Bone marrow involvement in solid tumors - a retrospective observational study.
Bicheng Zhang1, Lan Jin2, Dang Wu1
1Department of Radiation Oncology, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China.
Frontiers in Oncology
|September 24, 2025
Summary
Patients with solid tumors and bone marrow involvement (BMI) can benefit from aggressive treatment. Identifying prognostic factors aids in selecting patients who may respond well to therapy, improving survival outcomes.
Area of Science:
- Oncology
- Hematology
Background:
- Bone marrow involvement (BMI) in solid tumors often indicates a poor prognosis.
- Some patients with BMI still achieve good outcomes with aggressive treatment.
Purpose of the Study:
- To identify prognostic factors for stratifying solid tumor patients with BMI.
- To screen patients who may benefit from aggressive treatment.
Main Methods:
- Retrospective analysis of 41 solid tumor patients with BMI.
- Assessment of clinical features and laboratory data.
- Kaplan-Meier method for survival analysis.
Main Results:
- Median overall survival (OS) was 23 days for the cohort.
- Patients receiving anti-tumor treatment had significantly longer OS (158 days) than those receiving supportive care (13 days).
- Favorable prognostic indicators included normal leukocyte and platelet counts, normal GPT and PT, and specific LDH and AKP levels. Elevated LDH, AKP, GPT, prolonged PT, abnormal leukocyte counts, and thrombocytopenia were associated with poor prognosis.
Conclusions:
- Solid tumor patients with BMI can benefit from aggressive anti-tumor treatments.
- Early diagnosis and selection of patients with favorable prognostic factors are crucial for improving survival.
